Biocon Analyst Rating
based on 18 analysts
57.89%
Buy
15.79%
Hold
26.32%
Sell
Based on 18 analysts offering long term price targets for Biocon. An average target of ₹373.67
Source: S&P Global Market Intelligence
Biocon Share analysis
Biocon price forecast by 18 analysts
Downside of
High
₹460
Target
₹373.67
Low
₹235
Biocon target price ₹373.67, a slight downside of -6.94% compared to current price of ₹390.55. According to 18 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon revenue growth forecast
Expected growth rate Q1, FY2027:43.04%
Forecast
Actual
Including amortisation and stock based compensations
Biocon EPS growth forecast
EPS estimate Q1, FY2027:69.25%
Forecast
Actual
Source: S&P Global Market Intelligence
Biocon Performance
Day's Low
Day's High
₹389.25Day's Price Range₹404.752 Week's Low
52 Week's High
₹244.5552-Week Price Range₹404.7
| Returns % | |
| 1 Month Return | + 21.85 % |
| 3 Month Return | + 19.01 % |
| 1 Year Return | + 52.97 % |
| Market Stats | |
| Previous Close | ₹401.55 |
| Open | ₹403.00 |
| Volume | 46.81L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹48,210.09Cr |
Biocon Key Statistics
| P/E Ratio | 32.73 |
| PEG Ratio | 4.16 |
| Market Cap | ₹48,210.09 Cr |
| P/B Ratio | 2.91 |
| EPS | 10.81 |
| Dividend Yield | 0.19 |
| Sector | Pharmaceuticals |
| ROE | 0.97 |
Biocon Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹48,210.09 Cr | 7.26% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹1,59,297.08 Cr | 44.15% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,07,087.79 Cr | 42.65% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹27,623.92 Cr | -1.57% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,16,736.57 Cr | 41.07% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
About Biocon
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Share Price: ₹390.55 per share as on 21 Jan, 2025 04:01 PM
Market Capitalisation: ₹48,210.09Cr as of today
Revenue: ₹3,545.00Cr as on September 2024 (Q3 24)
Net Profit: ₹27.10Cr as on September 2024 (Q3 24)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Biocon Ltd
Biocon Stock Hits New High Amid Positive Trends - 21 Jan, 2025
Biocon shares reached a new all-time high, with analysts recommending buying. The company is also recognized for its role in global pharma collaboration.Biocon Hits 52-Week High Amid Tax Exemption Call - 20 Jan, 2025
Biocon's chairperson, Kiran Mazumdar-Shaw, calls for tax exemptions on cancer and rare disease drugs ahead of the Union Budget. The stock reached a 52-week high, reflecting strong market performance with an 18% increase over the past month.Goldman Sachs' Investment in Biocon Faces Regulatory Issues - 18 Jan, 2025
Goldman Sachs entered into a Securities Subscription Agreement and Shareholders Agreement with Biocon in late 2020, but the investment violated CCI approval regulations under the Competition Act, 2002.Buy Recommendation for Biocon Stock Issued - 17 Jan, 2025
A buy recommendation for Biocon Ltd was issued at ₹393, with a target price of ₹410 and a stop loss set at ₹380.Biocon Stock Gains Amid Positive Developments and Upgrades - 16 Jan, 2025
Biocon shares rose 3.10% due to positive investor sentiment and upgrades from Motilal Oswal, targeting Rs 430. However, a penalty from CCI adds caution.Analyst Recommends Buy for Biocon Shares - 15 Jan, 2025
On January 15, 2025, analysts recommended buying Biocon shares, targeting Rs 450 with a stop loss at Rs 370. The stock shows bullish sentiment despite market volatility.Biocon Shares Surge After HSBC Upgrade and FDA Clearance - 14 Jan, 2025
Biocon's stock rose over 7% after HSBC upgraded it to 'Buy' with a target price of ₹430, citing an operational turnaround and FDA clearance of its Malaysia facility. The upgrade reflects confidence in Biocon's biosimilar pipeline and recovery in generics sales, positioning the company for significant growth.Biocon's Johor Facility Receives FDA VAI Classification - 12 Jan, 2025
Biocon Limited announced that the U.S. FDA classified its biologics manufacturing site in Johor Bahru, Malaysia, as Voluntary Action Indicated after a recent cGMP inspection.Biocon Biologics Marks Milestone Year with Inventory Goals - 08 Jan, 2025
Biocon Biologics celebrates its first year as a fully integrated global biosimilar enterprise post-Viatris acquisition, targeting a $100 million inventory improvement.Biocon Shares Surge on Psoriasis Drug Approval - 07 Jan, 2025
Biocon's subsidiary received approval from Japan's PMDA for Ustekinumab BS, a psoriasis treatment. Following this, shares rose 4%, and Jefferies upgraded the stock to Buy with a target of ₹400.Biocon Strengthens Portfolio with New Approvals and Hiring - 02 Jan, 2025
Biocon Ltd is expanding its generics and biosimilars business by hiring top executives and has received NMPA approval for Tacrolimus capsules, enhancing its market presence.Biocon Invests in CSR Initiatives for FY 2023-24 - 31 Dec, 2024
Biocon Limited and its subsidiaries have invested Rs. 31.54 crore in Corporate Social Responsibility for FY 2023-24, focusing on healthcare, education, rural development, environmental sustainability, and women empowerment, benefiting over 3.75 lakh individuals.Biocon Secures EU Approval and FDA Clearance - 24 Dec, 2024
On December 24, 2024, Biocon announced EU approval for generic Liraglutide, received VAI status from the US FDA for its Bengaluru API facility, and saw a 5% stock increase.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 5.90% to 5.93% in Sep 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, BIOCON stock has moved up by 3.3%
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Vimta Labs Ltd has given 111.6% return, outperforming this stock by 81.7%
- NO EFFECT
Against Peers
In the last 3 years, Shree Ganesh Remedies Ltd has given 129.0% return, outperforming this stock by 126.9%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 659.7 Cr → -16.0 Cr (in ₹), with an average decrease of 102.4% per quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 4.59K Cr → 3.64K Cr (in ₹), with an average decrease of 20.7% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 8.69% to 7.97% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 18.89% to 18.75% in Sep 2024 quarter
Biocon Financials
Index Inclusions
Biocon Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 60.64% | 0.00 | |
| Foreign Institutions | 5.93% | 0.47 | |
| Mutual Funds | 7.97% | ||
| Retail Investors | 18.75% | ||
| Others | 6.72% | 14.14 |
Biocon Key Indicators
Biocon Valuation
Biocon in the last 5 years
Lowest (24.48x)
March 19, 2024
Today (32.73x)
January 17, 2025
Industry (54.95x)
January 17, 2025
Highest (118.86x)
September 27, 2018
Biocon Earnings and Dividends
Biocon Ltd Earnings Results
Biocon Ltd’s net profit fell -112.74% since last year same period to ₹-16Cr in the Q2 2024-2025. On a quarterly growth basis, Biocon Ltd has generated -102.43% fall in its net profits since last 3-months.
Read More about Earnings ResultsBiocon Ltd Dividends May,2024
In the quarter ending March 2024, Biocon Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.51%.
Read More about Dividends
Biocon Technicals Summary
Bearish
Neutral
Bullish
Biocon Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Biocon Ltd
Biocon Ltd share price today stands at ₹390.55, Open. ₹403 ; Previous Close. ₹401.55 ; High. ₹404.7 ; Low. ₹389.25 ; 52 Week High. ₹404.7 ; 52 Week Low: ₹244.55.
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Biocon Ltd shares.
Biocon Ltd is listed on NSE
Biocon Ltd is listed on BSE
- Today’s highest price of Biocon Ltd is ₹404.7.
- Today’s lowest price of Biocon Ltd is ₹389.25.
PE Ratio of Biocon Ltd is 32.73
PE ratio = Biocon Ltd Market price per share / Biocon Ltd Earnings per share
Today’s traded volume of Biocon Ltd(BIOCON) is 46.81L.
Today’s market capitalisation of Biocon Ltd(BIOCON) is ₹48210.09Cr.
| Biocon Ltd(BIOCON | Price |
|---|---|
52 Week High | ₹404.7 |
52 Week Low | ₹244.55 |
Biocon Ltd(BIOCON) share price is ₹390.55. It is down -3.50% from its 52 Week High price of ₹404.7
Biocon Ltd(BIOCON) share price is ₹390.55. It is up 59.70% from its 52 Week Low price of ₹244.55
| Biocon Ltd(BIOCON | Returns |
|---|---|
1 Day Returns | -11% |
1 Month Returns | 21.85% |
3 Month Returns | 19.01% |
1 Year Returns | 52.97% |